Incyte | INCY - Koszty Sprzedaży





Koszty Sprzedaży Zmiana Data
Acadia Pharmaceuticals USD 28.32M 3.52M 2026-06
Agenus USD 642K 399K 2025-09
Agios Pharmaceuticals USD 1.32M 560K 2026-03
Alnylam Pharmaceuticals USD 298.45M 87.33M 2026-06
Amgen USD 1.87B 271M 2026-06
BioCryst Pharmaceuticals USD 3.84M 5.68M 2026-06
Biogen USD 945.1M 147.6M 2026-06
BioMarin Pharmaceutical USD 276.29M 76.8M 2026-06
Bristol-Myers Squibb USD 7.89B 4.03B 2026-06
Eli Lilly USD 3.27B 309M 2026-06
Exelixis USD 20.66M 704K 2026-06
Gilead Sciences USD 1000M 445M 2026-06
Incyte USD 104.96M 457K 2026-06
Ionis Pharmaceuticals USD 2.74M 261K 2026-06
MacroGenics USD 9.53M 585K 2026-03
Merck USD 3.14B 200M 2026-06
Moderna USD 93M 862M 2026-06
Nektar Therapeutics USD 4.43M 5.3M 2024-09
Neurocrine Biosciences USD 39.4M 25.6M 2026-06
Novartis USD 3.71B 251M 2026-06
Novartis USD 3.46B 83M 2026-03
Pfizer USD 4.09B 498M 2026-06
PTC Therapeutics USD 39.61M 23.31M 2026-03
Puma Biotechnology USD 29.1M 18.44M 2024-09
Regeneron Pharmaceuticals USD 576.5M 92.9M 2026-06
Sarepta Therapeutics USD 150.1M 40.64M 2026-06
Ultragenyx Pharmaceutical USD 30M 1000K 2026-03
Vertex Pharmaceuticals USD 489.2M 96.4M 2026-06